PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Morniflumate→

Morniflumate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
65847-85-0
Molecular formula
C19H20F3N3O3
Molecular weight
395.4 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)flufenamic-acid prodrug
Mechanism of action
Morniflumate is an ester prodrug hydrolysed to flufenamic acid, a fenamate NSAID that inhibits cyclooxygenase-mediated prostaglandin synthesis and reduces inflammation, pain and fever.
Indications / reported uses
  • Symptomatic treatment of pain and inflammatory conditions, including musculoskeletal and ENT inflammatory disorders, in countries where morniflumate is authorised.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=morniflumate · https://www.ncbi.nlm.nih.gov/mesh/?term=morniflumate · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Morniflumate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Morniflumate Permitted Daily Exposure (PDE) report (the Morniflumate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Morniflumate Occupational Exposure Limit (OEL) report (the Morniflumate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.